首页> 美国卫生研究院文献>Avicenna Journal of Medical Biotechnology >New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological Process
【2h】

New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological Process

机译:VEGF-A选择性剪接的新见解:病理过程中的关键调控转换。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vascular endothelial growth factor (VEGF-A) is one of the most important regulatory factors in pathological and physiological angiogenesis. Alternative splicing is a complicated molecular process in VEGF-A gene expression which adds complexity to VEGF-A biology. Among all VEGF-A exons, alternative splicing of exon 8 is the key determinant of isoform switching from pro-angio-genic VEGF-xxx to anti-angiogenic VEGF-xxxb. This is known as a key molecular switching in many pathological situations. In fact, the balance between VEGF-xxx and VEGF-xxxb isoforms is a critical controlling switch in both conditions of health and disease. Here, the properties of VEGF-xxx and VEGF-xxxb isoforms were discussed and their regulatory mechanism and their roles in certain pathological processes were evaluated. In summary, it was suggested that C-terminal VEGF-A alternative splicing can provide a new treatment opportunity in angiogenic diseases.
机译:血管内皮生长因子(VEGF-A)是病理和生理血管生成中最重要的调节因子之一。选择性剪接是VEGF-A基因表达中的复杂分子过程,这增加了VEGF-A生物学的复杂性。在所有VEGF-A外显子中,外显子8的可变剪接是从促血管生成VEGF-xxx转换为抗血管生成VEGF-xxxb的同工型的关键决定因素。在许多病理情况下,这被称为关键分子转换。实际上,在健康和疾病条件下,VEGF-xxx和VEGF-xxxb亚型之间的平衡都是至关重要的控制开关。在此,讨论了VEGF-xxx和VEGF-xxxb同工型的性质,并评估了它们的调节机制及其在某些病理过程中的作用。总而言之,有人提出C端VEGF-A的替代剪接可以为血管生成性疾病提供新的治疗机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号